HemaCare Names Dr. Scott Burger Scientific Advisory Board Chair

LOS ANGELES--()--HemaCare Corporation (OTCBB: HEMA) today named Scott R. Burger, MD as the Chairperson of its Scientific Advisory Board. HemaCare has also engaged Dr. Burger, a world renowned cell therapy expert, in a comprehensive consulting services agreement. Dr. Burger will be a key agent in the aggressive expansion of HemaCare’s role in the rapidly developing fields of stem cells and cellular therapies, regenerative medicine, and immunotherapy.

Dr. Burger’s appointment comes as HemaCare embarks on a significant expansion of its existing network of apheresis collection centers in the United States. In apheresis, patient blood is passed through a device that separates out desired constituents and returns the remainder to the circulation. His participation in this expanded effort enhances service to HemaCare’s rapidly growing customer base of biotechnology and pharmaceutical firms who depend on HemaCare for blood components for their research and clinical trials as well as their cellular therapy services.

“We are thrilled Dr. Burger has agreed to join forces with us. His expertise and scientific credibility are internationally known. Combining his extensive expertise in cell, gene and tissue therapies with HemaCare’s decades-long track record as an industry leader sparks an exciting new era in the development and commercialization of products for critically needed therapeutic applications,” said Pete van der Wal, President and CEO of HemaCare Corporation.

Dr. Burger received his M.D. from the University of Pennsylvania School of Medicine, followed by residency and fellowship training in Laboratory Medicine and Transfusion Medicine at Washington University in St. Louis. A frequent speaker at industry and academic conferences, Dr. Burger has authored over 100 scientific publications and presentations, won numerous honors and awards and is widely known a major thought leader in cell therapy circles.

ABOUT HEMACARE CORPORATION

HemaCare Corporation is a leading provider of human blood derived products and services for use in research studies, medical device qualifications, validations, and the development and commercialization of cellular therapies. HemaCare's customers include biotechnology and pharmaceutical companies, research organizations, and academic institutions. Together with its subsidiaries, the company engages in the collection, processing, and distribution of blood products to healthcare providers.

Contacts

HemaCare Corporation
Anna Stock, Chief Operating Officer
(818) 226-1968

Contacts

HemaCare Corporation
Anna Stock, Chief Operating Officer
(818) 226-1968